Procarta Biosystems Ltd

Procarta Biosystems is a UK based biotech company, developing a pipeline of antibacterial agents discovered using its proprietary Oligonucleotide Antimicrobial Discovery platform. The Company’s approach is to selectively deliver oligonucleotides to the cytoplasm of bacterial cells using its patented delivery system. The oligonucleotides are designed to inhibit a previously untapped set of antimicrobial targets, transcription factors, which leads to a precisely controlled spectrum of activity. The lead asset, PRO-202, targeting CRE bacteria, is in preclinical development to treat complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI).